Efficacy and safety of surufatinib and anti-PD-L1 therapy in combination with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma

doi:10.3748/wjg.122785

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 33, Issue 1

This Article

(2)

(0)

(89)

Peer-Review Report of This Article

Supplementary Materials of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2027. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jan 7, 2027; 33(1): 122785
Published online Jan 7, 2027. doi: 10.3748/wjg.122785

Table 2 Tumor response (n = 36), n (%)

Characteristics	RECIST
Complete response	0
Partial response	17 (47.2)
Stable disease	17 (47.2)
Progressive disease	2 (5.6)
Objective response rate, %	47.2
Disease control rate, %	94.4

RECIST: Response Evaluation Criteria in Solid Tumors.

Full Size Table

Citation: Zhao RC, Xiong XH, Zhou J, Lu LH, Mei J, Wei W, Guo RP. Efficacy and safety of surufatinib and anti-PD-L1 therapy in combination with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma. World J Gastroenterol 2027; 33(1): 122785
URL: https://www.wjgnet.com/1007-9327/full/v33/i1/122785.htm
DOI: https://dx.doi.org/10.3748/wjg.122785

Zhao RC, Xiong XH, Zhou J, Lu LH, Mei J, Wei W, Guo RP. Efficacy and safety of surufatinib and anti-PD-L1 therapy in combination with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma. World J Gastroenterol 2027; 33(1): 122785 [DOI: 10.3748/wjg.122785]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.